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expressed in cultured FLS from OA patients as well. Increased
RANKL expression in cultured FLS derived from RA patients has
been reported previously [4, 5]. In the presence of TNF-, RANKL
expression from FLS was signiﬁcantly decreased, as demonstrated
by RT-PCR analysis and northern blot analysis (Fig. 2B and C).
On the other hand, treatment of FLS from OA patients had no
effect on the induction of RANKL.
RANKL is the main osteoclast-stimulating factor and OPG
functions as a decoy receptor for RANKL, thereby acting as an
inhibitor of RANKL-mediated bone resorption. It is therefore
suggested that the balance between RANKL and OPG is impor-
tant in the regulation of the bone microenvironment [6]. Without
stimulation, FLS from our OA patients expressed a signiﬁcantly
increased level of OPG and a decreased level of RANKL compared
with active RA patients. OPG expression in FLS from OA patients
would be important in the protection of bone destruction. The
expression of OPG and RANKL in FLS from OA patients was not
signiﬁcantly altered even in the presence of the potent inﬂamma-
tory cytokine TNF-. In contrast, RANKL, but not OPG, was
abundantly expressed in FLS from our RA patients without
stimulation. In addition, RANKL and OPG expression in FLS
from RA patients was signiﬁcantly modulated in the presence of
TNF-. RANKL-dominant expression, along with the lack
of resistance against TNF- of FLS from RA patients, may
contribute to the pathogenesis of bone loss in RA.
The authors have declared no conﬂicts of interest.
S.-I. HARASHIMA, H. TSUKAMOTO, T. HORIUCHI
Medicine and Biosystemic Science, Kyushu University Graduate
School of Medical Sciences, Fukuoka 812-8582, Japan
Accepted 25 July 2003
Correspondence to: T. Horiuchi. E-mail:horiuchi@intmed1.
med.kyushu-u.ac.jp
1. Haynes DR, Barg E, Crotti TN et al. Osteoprotegerin expression in
synovial tissue from patients with rheumatoid arthritis, spondylo-
arthropathies and osteoarthritis and normal controls. Rheumatology
2003;42:123–34.
2. Horiuchi T, Macon KJ, Kidd KJ, Volanakis JE. cDNA cloning
and expression of human complement component C2. J Immunol
1989;142:2105–11.
3. Ziolkowska M, Kurowska M, Radzikowska A et al. High levels of
osteoprotegerin and soluble receptor activator of nuclear factor kB
ligand in serum of rheumatoid arthritis patients and their normal-
ization after anti-tumor necrosis factor  treatment. Arthritis Rheum
2002;46:1744–53.
4. Gravallese EM, Manning C, Tsay A et al. Synovial tissue in
rheumatoid arthritis is a source of osteoclast differentiation factor.
Arthritis Rheum 2000;43:250–8.
5. Takayanagi H, Iizuka H, Juji T et al. Involvement of receptor
activator of nuclear factor-B ligand/osteoclast differentiation factor
in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
Arthritis Rheum 2000;43:259–69.
6. Bolon B, Shalhoub V, Kostenuik PJ et al. Osteoprotegerin, an
endogenous antiosteoclast factor for protecting bone in rheumatoid
arthritis. Arthritis Rheum 2002;46:3121–35.
Rheumatology 2004;43:397
doi:10.1093/rheumatology/keh023
Reply
Harashima et al. produce some interesting results concerning
OPG and RANKL mRNA production by RA and OA synovial
ﬁbroblasts. Unfortunately, there are several reasons why it is
difﬁcult to relate the results of Harashima et al. to the results
presented in our recent paper [1].
No clinical details are provided on the RA or OA patients other
than a statement that the RA patients are ‘active’. It would be
helpful to know about disease duration, previous and current
treatment, joint scores and levels of inﬂammatory markers.
All the results from Harashima et al. relate to mRNA pro-
duction, and no evidence is presented to show that this mRNA
results in OPG and RANKL protein production.
In addition, all the results relate to type II synovial ﬁbroblasts
grown in tissue culture; there are no results relating to other
relevant inﬂammatory cell synovial inﬁltrates. Our immuno-
histochemical labelling results show that the major sources of
OPG protein are type I synovial macrophages and endothelial cells
[1], while the major source of RANKL protein was the lymphocyte
[2]. We were unable to demonstrate signiﬁcant OPG or RANKL
protein production by type I synoviocytes by immunohistochem-
istry on synovial tissue.
Finally, the effects of tumour necrosis factor- (TNF-) on OPG
and RANKL mRNA production shown by Harashima et al.
are not very impressive and do not appear to correlate with the
clinical situation. These authors suggest that TNF- treatment of
RA ﬁbroblasts increased OPG mRNA and decreased RANKL
mRNA, yet the active RA synovial ﬁbroblasts (in a clinical
situation in which increased TNF- is expected in the synovial
membrane) showed lower OPG and higher RANKL mRNA levels
than OA ﬁbroblasts. In addition, this would suggest that anti-TNF
treatments would decrease OPG mRNA and increase RANKL
mRNA levels in synovial ﬁbroblasts, leading to a situation in which
bone erosion should be increased. This is not what clinical trials on
anti-TNF treatment have suggested [3].
Perhaps the conclusion that can be drawn is that results from
studies undertaken in in vitro cell culture systems on isolated
cell populations from synovial tissue do not necessarily correlate
with what is seen in vivo in whole-tissue systems and should be
interpreted with caution.
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Statins and lupus erythematosus
SIR, I read with interest the article of Wajed et al. [1] regarding
the prevention of cardiovascular disease in systemic lupus
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erythematosus. Patients with systemic lupus erythematosus (SLE)
have a high prevalence of cardiovascular diseases due to premature
or accelerated atherosclerosis. Lowering cholesterol levels with
statin therapy is one of the main targets in reducing the morbidity
and mortality of SLE. However, these lipid-lowering agents may
have unexpected immunological effects.
An increasing number of cases of statin-induced lupus like
syndrome have recently been reported [2–4]. Most cases were
caused by second-generation statins, such as simvastatin and
atorvastatin. One case was associated with autoimmune hepatitis
[5]. Statins have also been implicated in drug-induced dermat-
omyositis and other types of autoimmune skin diseases, such as
lichen planus pemphigoides [6, 7]. In all cases of statin-induced
lupus, skin eruption was similar to that occurring in subacute lupus
erythematosus, with positive antinuclear antibodies. Unlike usual
drug reactions, the skin eruption was observed only many months
after the start of therapy and antinuclear antibodies were still
positive many months after drug discontinuation. A causal
relationship between drug intake and the autoimmune disease
may be therefore difﬁcult to establish.
Two pathogenic mechanisms may be suspected in statin-induced
lupus-like syndrome. Cellular apoptosis, which plays a crucial role
in SLE, may be exacerbated or triggered by second-generation
statins, which are potent pro-apoptotic agents [8]. The release of
nuclear antigens into the circulation may foster the production of
pathogenic autoantibodies. The same mechanism is implicated
with other environmental factors, such as ultraviolet light, which is
a well-known triggering factor in SLE. The direct immunomodu-
lator effect of statins on T lymphocytes is possibly also involved.
SLE is characterized by a shifting of T helper 1 (Th1) to Th2
immune responses, leading to B-cell reactivity and the produc-
tion of pathogenic autoantibodies. Statins may aggravate this
phenomenon [9, 10].
Statins are among the most widely prescribed drugs. Their
overall safety proﬁle is good. However, these drugs have not only
cholesterol-lowering properties but also have immunomodulator
effects, which may potentially trigger or aggravate autoimmune
diseases. Statin-induced lupus must be therefore considered in the
differential diagnosis of SLE.
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We are grateful to Dr Noe¨l, who points out the potential issue of
safety of statins, in particular whether they are actually capable of
inducing the development of SLE [1]. Firstly, he draws attention to
a number of case reports of patients, using a variety of statins, in
whom lupus-like syndromes have been reported. It is interesting,
given the large volume of prescribing of these agents in Western
society, how uncommon these reactions appear to be. In many
cases, as the author points out, causation has been difﬁcult to
conclusively establish [1].
There are nevertheless theoretical concerns regarding the
potential immunomodulatory effects of statins and whether
these may aggravate the propensity to develop SLE. In particular,
these agents shift the T helper responses towards a Th2 phenotype
[2]. While this would again be hypothesized to be detrimental in
SLE, it is probably an oversimpliﬁcation to assume that the
pathological features of SLE are entirely driven by a Th2
response. For example, interferon gamma (IFN-) appears to
have important effects in the context of SLE. Jacobs et al. have
demonstrated that IFN- can exacerbate lupus nephritis [3] and
others have noted that a subgroup of relevant nucleosomal histone
peptides stimulate IFN- production from autoreactive T cells [4].
An important effect of certain statins is to inhibit IFN--induced
expression of inducible MHC class II [5]. This reduces subsequent
T-cell proliferation and activation. Therefore, statins may actually
have potential to attenuate certain immune responses of relevance
in SLE.
There is no doubt that premature cardiovascular disease
represents a major challenge in the management of SLE patients.
There is also no doubt that, in all contexts in which they have been
studied, statins have great potential to safely and effectively reduce
the burden of cardiovascular disease. As such we recommend their
use in the context of SLE where the target LDL cholesterol cannot
be achieved by other means [6]. Our initial experience of
prescribing statins also suggests that cholesterol reduction can be
achieved without any obvious detrimental effects on the underlying
SLE. It is also our own view that these agents may actually have a
beneﬁcial effect on SLE disease activity, although we acknowledge
that it will take a well-designed trial to study in depth their
immunomodulatory potential in SLE.
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